11th Annual Meeting of International Cytokine & Interferon Society

摘要 本申请的目的是为细胞因子2023：第11届年会申请财政支持。 国际细胞因子和干扰素协会（ICIS），2023年10月15日至18日，与livestream和按需虚拟 访问到2023年10月29日。这次年会有助于弥合科学家之间的差距， 免疫细胞激活和功能的分子和细胞机制的基础研究， 将这些知识发展成新的疗法。第11版是在细胞因子生物学，细胞因子 生物标志物和细胞因子疗法正在彻底改变现代医学，为广泛的 各种疾病，从致命的炎症性、自身免疫性和过敏性疾病，到病毒感染， 癌今年的主题是“精准医学时代的细胞因子和干扰素”，聚焦最新的 与免疫调节、宿主损伤和疾病有关的细胞因子生物学的发展， 细胞因子/细胞因子抑制剂作为临床新疗法的进展。 在全体会议和平行会议上，该领域的领导人将讨论各种主题， 免疫和宿主防御，适应性免疫，T和B细胞对疫苗接种反应中的细胞因子， COVID、HIV和新型靶向疗法，从癌症免疫疗法到自身免疫的新型疗法。 由于会议的一个主要目标是促进科学家和临床医生之间的互动， 翻译或应用研究，将给予充分的机会，海报网络会议，提出 最新进展涉及细胞因子研究，生物标志物和治疗。更好地理解机制 疾病和治疗的新概念已经并将继续从跨学科的聚会中出现 在那里，成熟的和实习的科学家可以展示和讨论进展。 会议将重点关注个性化医疗中的细胞因子，并将为更新 在这些领域开发新的治疗干预措施，并帮助促进国际合作， 会议的与会者。虽然与会者将主要关注传染病，癌症， 和免疫介导的疾病，该计划整合了细胞因子和干扰素周边的扬声器 研究，以帮助桥梁这些学科。这种跨学科的环境对于早期的 职业研究人员不仅专注于自己的研究领域，而且开始思考 更广泛的影响他们的工作。我们的目标是增加早期职业调查员和受训人员的出勤率， 此外，还应提高代表性不足的少数群体在各级职业发展中的代表性。 在线演示将包括所有允许的发言者的现场视频演示 以便于虚拟与会者以及亲自与会者从并行访问内容 会议或错过的介绍。ICIS会议委员会和理事会决定， 即使在没有旅行限制的情况下，也可以访问，使年会更具包容性和可持续性。

ABSTRACT The purpose of this application is to request financial support for Cytokines 2023: 11th Annual Meeting of the International Cytokine & Interferon Society (ICIS), October,15-18, 2023, with llivestream and on-demand virtual access through October 29, 2023. This Annual Meeting helps bridge the gap between the scientists performing basic research on molecular and cellular mechanisms of immune cell activation and function with those working to develop this knowledge into novel therapies. The 11th edition comes at a time when cytokine biology, cytokine biomarkers and cytokine therapeutics are revolutionizing modern medicine, providing novel treatments for a wide variety of diseases ranging from lethal inflammatory, autoimmune and allergic diseases, to viral infections and cancer. This year’s theme is “Cytokines and interferons in the precision medicine era”, focusing on the latest developments on cytokine biology in relation to immune regulation, host damage and disease, and the latest progress on cytokines/cytokine inhibitors as novel therapeutics in the clinic. A variety of topics will be covered by leaders in the field in the plenary and parallel sessions such as innate immunity and host defense, adaptive immunity, cytokines in T and B cell responses to vaccination, in Long COVID, HIV and novel targeted therapies from cancer immunotherapy to novel therapeutics in autoimmunity. Since a major goal of the meeting is to promote interactions between scientists and clinicians working in basic, translational or applied research, ample opportunity will be given to poster networking sessions to present the latest advances elated to cytokine research, biomarkers and therapeutics. Greater understanding of mechanisms of disease and novel concepts for therapy have and will continue to emerge from interdisciplinary gatherings where advances can be presented and discussed by established and trainee scientists. The meeting will focus on cytokines in personalized medicine and will provide an opportunity for updates on the development of novel therapeutic interventions in these fields and help spur international collaborations among the meeting participants. Although meeting participants will have primary interests in infectious diseases, cancer and immune-mediated diseases, the program integrates speakers on the periphery of Cytokine and Interferon research to help bridge these disciplines. This interdisciplinary environment is particularly interesting for early career researchers who are not only focused on their own field of research but are beginning to think about the wider implications of their work. Our goal is to increase attendance of early career investigators and trainees and also to achieve higher representation of underrepresented minorities at all levels of career development. Online presentations will consist of livestreamed video presentations for all speakers who give their permission to be recorded, to benefit virtual attendees as well as in-person attendees to access content from parallel sessions or missed presentations. ICIS Meetings Committee and Council have decided that included virtual access even without travel restrictions, makes the Annual Meeting more inclusive and sustainable.